Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone vs Paclitaxel with Carboplatin in Advanced NSCLC
NCT00723957Phase 2Completed
- Sponsor
- R-Pharm
- Start
- Dec 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised trial of ixabepilone in non-small cell lung cancer (NSCLC) (2 arms), sponsored by R-Pharm. Primary endpoint: Progression-free Survival in the Subgroup of Participants With beta III-tubulin Positive Tumors up to 14.39 months. Started Dec 2008; status: completed.
02
Drugs
ixabepilone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00723957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00723957.